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Background: Nonadherence to antiepileptic drugs (AEDs) can result in suboptimal outcomes for patients.
Aim: This study aimed to assess the utility of a theory-based approach to understanding patient perspectives on
AEDs and adherence.
Method: Patients with epilepsy, identiﬁed by a GP case note review, were mailed validated questionnaires
assessing their perceptions of AEDs and their adherence to them.
Results:Most (84.9%) of the 398 AED-treated respondents accepted the necessity of AEDs, but over half expressed
doubts, with 55% disagreeing or uncertain about the statement ‘I would prefer to take epilepsy medication than
risk a seizure’. Over a third (36.4%) expressed strong concerns about the potential negative effects of AEDs. We
used self-report and medication possession ratio to classify 36.4% of patients as nonadherent. Nonadherence
was related to beliefs aboutmedicines and implicit attitudes toward AEDs (pb0.05). Adherence-related attitudes
toward AEDs were correlated with general beliefs about pharmaceuticals (BMQ General: General Harm, General
Overuse, and General Beneﬁt scales) and perceptions of personal sensitivity to medicines (PSM scale).
Conclusion: We identiﬁed salient, adherence-related beliefs about AEDs. Patient-centered interventions to
support medicine optimization for people with epilepsy should take account of these beliefs.
© 2013 The Authors. Published by Elsevier Inc. 
1. Introduction
The most common treatment modality for people with epilepsy is
antiepileptic drugs (AEDs), and these drugs can offer seizure control
for over 70% of patients newly diagnosed with epilepsy [1]. However,
there is a ‘treatment gap’ for some people with epilepsy, particularly
in low-income countries [2], and suboptimal patient outcomes and
reduced quality of life are reported internationally [3,4]. Nonadherence
to AEDs can exacerbate the impact of suboptimal care [5] andmay result
in a 21% increase in the risk of seizures [6]. Between a quarter and two-
thirds of patientswith epilepsy do not take theirmedicines as prescribed
[4,6]. However, adherence is rarely discussed in consultations, and the
problem of nonadherence is often hidden: undisclosed by patients and
unrecognized by clinicians [7,8]. Nonadherence is a common but hidden
factor in treatment failure. People who are nonadherent to medicines
can be identiﬁed using a combination of proxy measures [9], but
patients and professionals should be assisted to better understand the
factors contributing to nonadherence and so improve care for people
with epilepsy.
Medicine-taking behavior is dynamic and variable across individ-
ual patients, and nonadherence can be intentional or unintentional.
Nonadherence may arise from a lack of motivation to take medicines
as prescribed due to perceptual barriers such as concerns about adverse
effects, doubts about a personal need for medicines, or gaps in
knowledge [10–12]. Practical barriers such as difﬁculty in opening pill
caps or difﬁculties with supply [10,13] can also prevent patients from
taking their medicines as prescribed.
The Necessity–Concerns Framework (NCF) postulates that adher-
ence to treatments is the result of the interplay between patients' beliefs
in their personal need for treatment (Necessity) and their concerns
about the potential adverse consequences of treatment (Concerns)
[14]. A recent systematic review of studies assessing the relationship
between adherence and treatment beliefs conﬁrmed that the odds of
nonadherence were signiﬁcantly increased when patients reported
high concerns and low necessity beliefs [15]. Patients' beliefs about
prescribed medicines (e.g., necessity beliefs and concerns) may differ
from the views of professionals, derived from evidence of the likely
beneﬁts and risks of the treatment. However, they are often based on a
common-sense understanding of the illness and treatment [16].
Patients' evaluations of speciﬁcmedicines prescribed for themmaybe
inﬂuenced by more general ‘background’ beliefs about pharmaceuticals
as a class of treatment [14] and by perceptions of personal sensitivity to
medicines [16,17]. For example, patients who believe that medicines are
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generally beneﬁcial will perceive higher personal necessity of treatments,
whereas those who believe that medications are generally harmful and
overused and that they are personally sensitive to the effects of treatments
will have more concerns about speciﬁc treatments [18,19].
Annual reviews have been recommended as a method to improve
epilepsy care [20] and offer the patient and their healthcare professionals
an opportunity to discuss the individual's beliefs about medicines.
Interventions to improve adherence to AEDs have had mixed success
[21]. However, the annual review provides an opportunity to improve
clinical outcomes through improving adherence.
The current study, therefore, investigated and quantiﬁed patients'
beliefs about medicines within a UK community sample of patients with
epilepsy, and the role of beliefs in nonadherence toAEDs. Previous studies
have established a role for beliefs aboutmedicines in nonadherence in US
specialty epilepsy clinics [10,11,22]; however, it is not clearwhether these
ﬁndings would extend to community samples or outside the US. We
hypothesized that patients who have concerns about the potential
adverse consequences of AEDs and doubts about the personal necessity
of AEDs would be more nonadherent and that these speciﬁc beliefs
about AEDs would be correlated with general background beliefs about
medicines as a class of treatment. We also explored whether demo-
graphic and clinical factors were associated with these beliefs.
2. Materials and methods
This study received ethical approval from the North Eastern MREC
and research governance approval from the North Yorkshire Research
Alliance and the West Hull PCT and Eastern Hull PCT.
All participants provided consent by accepting the invitation to
participate and completing the postal questionnaire.
2.1. Participants
Adult patients with epilepsy were identiﬁed from 27 GP practices in
3 primary care trusts (Selby/York PCT, West Hull PCT, and Eastern Hull
PCT) through a case note review conducted by DH and WHS [23].
Patients who were incorrectly coded as having epilepsy or who were
misdiagnosed were excluded to ensure that the target population
included all adults (aged 18 or older) with epilepsy at the identiﬁed
practices. Patients were excluded if they had a learning disability or
memory impairment and if their GP thought that they would not be
able to complete the questionnaire or that they would be distressed
by the questionnaire. Patients were also excluded if they had left the
practice or died by the time questionnaires were distributed. From
a total practice population of 161,500, 1333 adults with epilepsy
were identiﬁed, 832 questionnaires were sent out, and 461 (55%)
were returned, of which 438 were completed responses. Of these, 398
(91%) patients who reported that they were currently taking AEDs
were selected for analysis within the current study.
2.2. Measures
2.2.1. Demographics
Patientswere asked toprovide their age in years, gender, employment
status (employed, retired, homemaker, in education, unemployed, or
other), marital status (married/cohabiting, single, divorced, widowed,
living with parents or relatives, or living alone), and highest level of
educational qualiﬁcation obtained (school-leaving qualiﬁcation aged
16 years, advanced-level school-leaving qualiﬁcations, diploma/degree,
or no formal qualiﬁcation).
2.2.2. Seizure and epilepsy history
Patients were asked howmany seizures they had had in the past year,
how long it had been since their last seizure, whether they tended to have
seizures when awake or asleep, if they had a family history of epilepsy,
and how old they were when they were diagnosed with epilepsy.
2.2.3. Beliefs about Medicine Questionnaire (BMQ)
The BMQ [14,24] (copyright R. Horne) comprises two sections. The
BMQ-Speciﬁc assesses beliefs about speciﬁc medicines prescribed for
a particular condition (e.g., asthma, depression, and epilepsy), and the
BMQ-General assesses more general beliefs about pharmaceuticals as
a class of treatment [14].
2.2.3.1. BMQ-Epilepsy Speciﬁc. The BMQ-Speciﬁc [14] was adapted for an
epilepsy population as recommended in the literature [22]. It comprised
two scales: a 6-itemAED-Necessity scale, assessing patients' perceptions
of their personal need for AEDs and a 10-item AED-Concerns scale,
assessing concerns about the potential negative effects of taking AEDs.
The ﬁve core items of the BMQ-Speciﬁc Necessity scale [14] were
augmented by an additional epilepsy-speciﬁc item ‘I would prefer to
take my epilepsy medicine rather than risk having a seizure’. The ﬁve
core items of the BMQ-Speciﬁc Concerns scale were augmented by ﬁve
more epilepsy-speciﬁc items: ‘My epilepsy medicine causes unpleasant
side effects’, ‘Taking my epilepsy medicines makes me feel labeled as
an ‘ill person”, ‘I have received enough information about my epilepsy
medicines’ (reverse scored), ‘I sometimes worry that my antiepileptic
medicine slows me down’, and ‘I sometimes worry that my epilepsy
medicines affect my relationship with others’.
The resultingBMQ-Epilepsy Speciﬁc scaleswere reviewed by a study
panel comprising epilepsy patients, clinicians, and the study team. Post
hoc Cronbach'sα demonstrated that the internal reliability of the BMQ-
Epilepsy Speciﬁc scales was acceptable (AED-Necessityα=0.836; AED-
Concerns α=0.839).
All BMQ-Epilepsy Speciﬁc items were scored on a ﬁve-point Likert-
type scale (where 1 = strongly disagree, 2 = disagree, 3 = uncertain,
4=agree, and 5=strongly agree). By summing scores on the individual
items, AED-Necessity and AED-Concerns scale scores were computed.
A mean item score (range: 1–5) was then computed by dividing the
scale score by the number of items in the scale. Higher scores indicate
higher agreement with the construct represented by the scale.
ANecessity-ConcernsDifferential (NCD)was calculated by subtracting
AED-Concerns scores fromAED-Necessity scores. The NCD score provides
a numerical indicator of how the individual judges their personal need
for AEDs relative to their concerns about the potential negative effects
of taking AEDs. It provides a one-dimensional indicative representation
of the outcome of a ‘cost–beneﬁt evaluation’ where the assessment
is likely to be implicit, rather than a purely ‘rational’ assessment of
beneﬁts and costs [19,25]. The NCD scores range from−4 to +4, with
positive scores indicating higher ratings of AED-Necessity relative to
AED-Concerns.
Finally, we divided patients into 4 attitudinal groups by dichot-
omizing participants based on whether they scored over the AED-
Necessity and AED-Concerns scale midpoint of 3. Participants were
then grouped into patients who were Accepting (High Necessity and
Low Concerns), Indifferent (Low Necessity or Low Concerns), Skeptical
(Low Necessity or High Concerns), or Ambivalent (High Necessity or
High Concerns) about AEDs [16,26].
2.2.3.2. BMQ-General. The BMQ-General questionnaire has three
subscales. (1) General Harm (5 items) assesses perceptions of the
intrinsic properties of medicines and the degree to which they are
perceived as fundamentally harmful, addictive poisons, e.g., ‘Medicines
do more harm than good’ and ‘All medicines are poisons’. Although in
the original BMQ validation paper [24] this was a 4-item scale, one
item (‘Natural remedies are safer than medicines’) loaded onto both
General Overuse and General Harm factors, with only a slightly greater
loading on General Overuse. In some subsequent studies, including in
the current sample, this item loaded more strongly onto the General
Harm scale and so is included in the General Harm scale below.
(2) General Overuse (3 items) assesses perceptions of how medicines
are prescribed and the degree to which they are perceived as being
overused by clinicians, e.g., ‘Doctors place too much trust in medicines’
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and ‘If doctors had more time they would prescribe fewer medicines’.
(3) General Beneﬁt (4 items) assesses perceptions of the general
beneﬁts of pharmaceuticals, e.g., ‘In most cases the beneﬁts of medi-
cines outweigh the risks’ and ‘Medicines help many people to live
better lives’.
All BMQ-General itemswere scored on a ﬁve-point Likert-type scale
(where 1=strongly disagree and 5=strongly agree). Scale scores were
computed by summing scores on the individual items. A mean item
score (range: 1–5) was then computed by dividing the scale score by
the number of items in the scale. Higher scores indicate higher
agreement with the construct represented by the scale. Within the
current sample, the scales had acceptable internal reliability (General
Overuse Cronbach's α= 0.741, General Harm Cronbach's α= 0.579,
and General Beneﬁt Cronbach's α=0.538).
2.2.4. Perceived Sensitivity to Medicines (PSM) scale
The PSM [17] comprises 5 items assessing perceptions of personal
susceptibility to the effects of medicines, e.g., ‘My body overreacts to
medicines’ and ‘I usually have stronger reactions to medicines than
most people’. Perceived sensitivity to medicines items were scored
on a ﬁve-point Likert-type scale (where 1 = strongly disagree and
5 = strongly agree). Scale totals were computed by summing scores
on the individual items. A mean item score (range: 1–5) was then
computed by dividing the scale score by the number of items in the
scale. Higher scores indicate higher agreement with the construct
represented by the scale. The PSM scale had acceptable internal
reliability within the study sample (Cronbach's α=0.842).
2.2.5. Adherence assessment
Patients were grouped into adherent vs. nonadherent categories
using a combination of self-report and medication possession ratio.
2.2.5.1. Self-reported medication-taking behavior. This was assessed by
using 2 items from the Epilepsy Self-Management Scale (ESMS) [5]:
‘I skip doses of my seizure medication because I do not remember to
take it’ and ‘I skip doses of my seizure medication’. Items were scored
1–5 based onwhether participants reported ‘never’, ‘rarely’, ‘sometimes’,
‘most of the time’, or ‘always’ being nonadherent. These scores were
summed resulting in a score range of 0–10, with higher scores indicating
greater adherence.
2.2.5.2. Medication possession ratio (MPR). This provided a further
indicator of medication-taking behavior. Medication possession ratio
was calculated using patients' medication records [27].
2.2.5.3. Combining self-report and MPR. Where MPR was calculated as
b0.8 or the self-reported adherence score was less than 8 out of 10,
patients were classed as ‘nonadherent’, and where patients scored 9 or
10 on the self-report measure andMPRwas calculated as N0.8, patients
were classed as adherent. For 18 (4.6%) patients, it was not possible to
calculateMPR data frommedication records, and so theywere classiﬁed
on the basis of their self-reported adherence scores alone.
2.3. Analysis
Associations between adherence and demographic, clinical, and
attitudinal predictorswere tested using independent t-tests (relationship
of attitudes with high/low adherence, educational qualiﬁcations, gender,
and seizure history), correlations (relationships between attitudes and
relationship between age and attitudes), χ2 tests (relationship between
attitudinal groups and high/low adherence), and logistic regression
(prediction of low adherence using attitudinal variables). Two-tailed
tests and α=0.05 were used to assess the statistical signiﬁcance of the
results. Analyses were conducted using IBM SPSS Statistics v21. Where
fewer than half of item scoresweremissing from a participant's response
on the BMQ or PSM, scores were prorated.
3. Results
3.1. Patient demographics and seizure frequency
Just over half (54.6%) of the respondents were female. Themean age
of the patients sampled was 49.9 years. Most (60.8%) were married/
cohabiting, 40.4% were employed, and 43.0% had no educational
qualiﬁcations (see Table 1). Over half (59.1%) of the sample had not
had a seizure in the past year, and 36.9% had had a seizure in the
previous year. The mean age when diagnosed with epilepsy was
25.12years (sd=16.26).
3.2. Perceptions of medication
3.2.1. Perceptions of AEDs
We dichotomized the AED-Necessity and AED-Concerns scales at
their midpoint. Most patients were convinced of their personal need
for AEDs; however, 15.1% of the patients expressed strong doubts
about the necessity of AEDs (scores Nmidpoint on the AED-Necessity
scale). Over a third (36.4%) expressed strong concerns about the
potential negative effect of taking AEDs (scores N midpoint on the
AED-Concerns scale).
A more comprehensive insight into patients' views about their AEDs
is provided by an analysis of responses to the individual items on the
AED-Necessity and AED-Concerns scales (Figs. 1 and 2, respectively).
Although most patients broadly endorsed statements about their
personal need for AEDs (scoresNmidpoint on the AED-Necessity scale),
many expressed doubts about the necessity for AEDs. For example,
55.5% doubted that ‘Without my epilepsy medicines I would be very ill’,
and 53.0%were uncertain or disagreedwith the statement ‘I would prefer
Table 1
Participant clinical and demographic information.
m (sd)
Age (years)d 49.92 (16.44)
n (%)
Femalea 215 (54.6%)
Employmentb
Employed 159 (40.4%)
Retired 111 (28.2%)
Houseworker 40 (10.2%)
In education 7 (1.8%)
Unemployed 34 (8.6%)
Marital statusc
Married/cohabiting 240 (60.8%)
Single 70 (17.7%)
Divorced 37 (9.4%)
Widowed 21 (5.3%)
Highest educational qualiﬁcationd
Diploma/degree 79 (20.7%)
AS/A levels 23 (6.0%)
CSE/GCSE/O levels 108 (28.3%)
Other (NVQ) 1 (0.3%)
No qualiﬁcations 171 (43.0%)
Number of seizures in the past yeare
None 222 (56.5%)
1–10 90 (22.9%)
N10 81 (20.6%)
Time since last seizuref
b1 year 156 (44.7%)
1–5 years 98 (28.1%)
N5 years 95 (27.2%)
a 16 patients missing.
b 4 patients missing.
c 3 patients missing.
d 16 patients missing.
e 5 patients missing.
f 49 patients missing.
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to take my epilepsy medicine rather than risk having a seizure’. Likewise,
individual concerns were prevalent, with 47.8% patients concerned
about the long-term effects of AEDs and 42.2% reporting concern that
AEDs ‘slow me down’.
3.2.2. Attitudinal analysis of perceptions of AEDs
Participants were categorized into attitudinal groups based on
whether they scored above or below the scale midpoint for the AED-
Necessity and AED-Concerns scales [26]. Just over half of respondents
were completely Accepting of AEDs as deﬁned by higher-than-midpoint
scores on the AED-Necessity scale and lower-than-midpoint scores
on the AED-Concerns scale. Approximately a third were Ambivalent,
having high necessity beliefs and high concerns. The remainder were
Skeptical, having low necessity beliefs and high concerns, or Indifferent,
having low necessity and low concerns (see Fig. 3).
3.2.3. General beliefs about pharmaceuticals as a class of treatments
Participants were categorized into groups holding high or low
beliefs about pharmaceuticals as a class of treatment based on the
scale midpoint. Most patients believed that medicines were generally
beneﬁcial, with 95.5% (n = 380) scoring above the scale midpoint.
Only 20.9% (n = 83) indicated a high belief that medicines were
24.1%
33.2%
45.0%
47.5%
53.0%
55.5%
0% 10% 20% 30% 40% 50% 60%
My epilepsy medicines protect me from becoming worse.
My health at present depends on my epilepsy medicines.
My health in the future will depend on my epilepsy
medicines.
My life would be impossible without my epilepsy
medicines.
I would prefer to take my epilepsy medicine rather than
risk having a seizure.
Without my epilepsy medicines I would be very ill.
Fig. 1. Percentages of patients expressing doubts about their need for AEDs, as indicated by responding ‘uncertain’, ‘disagree’, or ‘strongly disagree’ on AED-Necessity items.
17.0%
19.0%
26.9%
28.1%
28.0%
28.5%
30.7%
32.2%
42.2%
48.7%
0% 10% 20% 30% 40% 50% 60%
My epilepsy medicines disrupt my life.
My epilepsy medicine causes unpleasant side effects.
Having to take epilepsy medicines worries me.
I sometimes worry about becoming too dependent on my
epilepsy medicines
I sometimes worry that my epilepsy medicines affect my
relationship with others.
Taking my epilepsy medicines makes me feel labelled as an
'ill person'
My epilepsy medicines are a mystery to me.
I have received enough information about my epilepsy
medicines (R)
I sometimes worry that my anti-eplieptic medicines slow
me down.
I sometimes worry about the long-term effects of my
epilepsy medicines.
Fig. 2. Percentages of patients expressing concerns about AEDs, as indicated by responding ‘agree’ or ‘strongly agree’ to AED-Concerns items.
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generally harmful. However, 58.9% (n = 234) had a high belief that
medicines are generally overused (see Fig. 4).
3.3. Perceived sensitivity to medicines
Just under a third of participants viewed themselves as highly
sensitive to the effects of medicines, (30.8%, n = 122), scoring above
the scale midpoint.
3.4. Relationship between speciﬁc beliefs about AEDs andgeneral background
beliefs about medicines
As predicted by our theoretical model [18], AED-Necessity beliefs
were signiﬁcantly positively correlated with General Beneﬁt beliefs.
General Harm, General Overuse, and PSM were signiﬁcantly positively
correlated with AED-Concerns. The NCD was negatively associated
with General Harm, General Overuse, and PSMand positively associated
with General Beneﬁt (all pb0.001) (see Fig. 5 for correlations).
3.5. Adherence to AEDs
Approximately one-third of the patients were placed in the low
adherence category based on their combined MPR rating and self-
report responses, n=146 (36.7%), with the remainder allocated to the
high adherence category, n=252 (63.3%).
3.6. Adherence and speciﬁc beliefs about AEDs, general beliefs about
medicines, and perceived sensitivity to medicines
Analysis of the Speciﬁc belief scales indicated that nonadherent
patients had a stronger belief in their personal need for AEDs and
more concerns about their potential adverse effects (p b .05). The NCD
score was signiﬁcantly lower in the nonadherent patients, indicating
that their beliefs in their personal need for AEDs were more closely
matched to concerns about their treatment (see Fig. 6).
Nonadherent patients also believed that medicines were generally
more overused and harmful, as indicated by General Harm and General
Overuse scores. However, the groups did not differ signiﬁcantly on the
General Beneﬁt and PSM scales (see Table 2).
Logistic regression analysis indicated that the odds of nonadherence
were signiﬁcantly increased when patients' concerns about AEDs
increased and signiﬁcantly reduced when beliefs in their personal
need for AEDs, the NCD, and beliefs in the harm and overuse of
medicines, in general increased (Table 3). The General Beneﬁt and
PSM scores did not signiﬁcantly predict nonadherence.
3.7. Attitudinal analysis of beliefs about AEDs for regular use
and nonadherence
Nonadherence rates varied signiﬁcantly across attitudinal groups,χ2
(3, n=396)=14.93, p=0.002. More than half (61.9%) of the Skeptical
participants were nonadherent, a lower proportion of Ambivalent
and Indifferent participants were nonadherent (44.4% of Ambivalent
participants; 41.0% of Indifferent participants), and only 28.8% of
Accepting participants were nonadherent (see Fig. 7).
3.8. Seizure history and beliefs about medicines
Patients who did not report a seizure in the past year had more
negative speciﬁc beliefs about medicines compared with patients who
reported one or more seizures within the past year. These patients also
had higher scores on the General Harm and PSM scales (see Table 4).
Post hoc tests indicated that AED-Necessity was higher in patients
who had a seizure within the past year than in patients who had had a
seizure more than 5 years ago. In patients who had had a seizure in the
past year than other patients, AED-Concerns, General Harm beliefs, and
PSM were higher. No other contrasts were signiﬁcant at the 0.05 level.
3.9. Demographic factors and beliefs about medicines
Personal sensitivity to medicines scores were higher in female
(m = 2.60, s = 0.79) than in male patients (m = 2.38, s = 0.76,
t(390) = 2.68, p b 0.01). No other signiﬁcant gender differences in
beliefs were found.
There was a negative correlation between patient age and AED-
Concerns indicating that younger patients tended to have greater
concerns, r(380) = −0.184, p b 0.001 and a lower NCD score,
r(380)=0.204, p b 0.001. General Beneﬁts scores were higher in older
Low AED-
Necessity
Indifferent
n = 39
9.8%
Skeptical
n = 21
5.3%
Ambivalent
n = 124
31.3%
Accepting
n = 212
53.5%
High AED-Concerns
High AED-
Necessity
Low AED-Concerns
Fig. 3. Attitudinal analysis of patients' beliefs about AEDs.
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patients, r(382) = 0.128, p b 0.05. No other signiﬁcant associations
between beliefs and age were found.
Relative to patients with no educational qualiﬁcations, patients with
qualiﬁcations including CSE/GCSE/O levels, AS or A levels, or diplomas
or degrees had lower AED-Necessity scores and lower NCD scores,
indicating more negative beliefs about their speciﬁc medicine (see
Table 5).
4. Discussion
To our knowledge, this study is the ﬁrst to assess the treatment
beliefs of a UK community sample of patients with epilepsy and to
evaluate the role of medication perceptions in adherence to AEDs
in this group. We found that most patients were convinced of the
necessity of AEDs, but 15% doubted their personal need for AEDs.
Almost a third of patients reported strong concerns about the
potential negative effects of AEDs. Beliefs about AEDs were related
to nonadherence. Nonadherent patients were signiﬁcantly more
likely to have negative perceptions of their AED medication, with
stronger doubts about their personal need for AEDs and stronger
concerns about potential harm.
A further insight into patients' implicit evaluations of AEDs was
provided by an attitudinal analysis combining AED-Necessity and
Concern ratings. Attitudinal analysis showed that most patients were
Accepting of their AEDs (high AED-Necessity with low AED-Concerns).
Skeptical patients who had high doubts about their need for AEDs and
concerns about the potential adverse effects were more likely to be
nonadherent.
These results indicate that patients with epilepsy may not adhere to
their AEDs, in part, because of negative beliefs about their medicines,
conﬁrming the applicability of the Necessity–Concerns Framework
[28] to this UK community sample. These ﬁndings are consistent with
previous ﬁndings in US specialist care [10,11,22] and with results in
patients with a range of long-term conditions [15].
Fig. 4. Frequency distributions for general background beliefs about medicines in this sample of patients with epilepsy.
317S.C.E. Chapman et al. / Epilepsy & Behavior 31 (2014) 312–320
Within the Necessity–Concerns Framework, adherence to medi-
cations is inﬂuenced by patients' evaluation of their personal need for
AEDs against their concerns about the potential adverse consequences
of the medication. Moreover, theories of medication representation
[19,29] suggest that patients' implicit evaluations of speciﬁc medication
prescribed for them are inﬂuenced by more general background beliefs
about medicines, including social representations of pharmaceuticals
as a class of treatments and perceptions of personal sensitivity to
medicines. Our ﬁndings support this model in that patients with more
negative perceptions about pharmaceuticals as a class of treatment
and those who perceived themselves to be more sensitive to the effects
of medicines had signiﬁcantly stronger concerns about their AEDs and
were, in turn, signiﬁcantly more likely to be nonadherent.
Beliefs about medicines were associated with clinical and demo-
graphic factors within the sample, such that patients had two or
more seizures in the past year reported more concerns about their
epilepsy medicines and were more likely to believe that they were
generally sensitive to the effects of medicines and that medicines
are generally harmful. However, they also believed that they had a
greater need of their epilepsy medicines. Female patients with epilepsy
perceived their personal sensitivity tomedicines to be higher thanmale
patients. Younger patients were more concerned about the potential
adverse consequences of medicine, and patients with any educational
qualiﬁcations (school-leaver, vocational, degree and postgraduate
qualiﬁcations) had more doubts about their personal need for
medicines (AED-Necessity) comparedwith patientswithout any formal
qualiﬁcations.
This study has several limitations. Firstly, it was an observational,
cross-sectional study, and, therefore, cannot assess whether treatment
beliefs cause nonadherence. Moreover, it is possible that the relation-
ships described above may not be generalizable to those patients who
did not respond to the survey and to populations in other healthcare
settings (e.g., secondary care) or to other locations (e.g., outside the
UK). Medication beliefs may vary across different cultural groups [30];
however, we did not investigate cultural factors within the present
study. Prospective longitudinal designs in a wide range of settings are
needed to fully assess whether beliefs can be used to predict later
nonadherence. We also did not use a validated measure of adherence
assessment. Although the Epilepsy Self-Management Scale has been
validated as ameasure of general self-management behavior in epilepsy
[5], the individual items were not recommended for use in this way.
AED-Necessity
AED-Concerns
NCD
General Benefit
General Harm
General Overuse
PSM
General Benefit
General Harm
General Overuse
PSM
0.264***
0.356***
0.360***
0.472***
0.290***
-0.355***
-0.381***
-0.256***
Fig. 5. Correlations between speciﬁc beliefs about AEDs and general background beliefs.
*** p b 0.001.
Fig. 6. AED-Necessity and AED-Concerns scores in adherent and nonadherent patients.
Table 2
Adherent and nonadherent patients' beliefs about medicines.
Nonadherent
n=143
m (sd)
Adherent
n=252
m (sd)
AED-Necessitya 3.64 (0.75) 3.92 (0.78) t(392)=3.63, p b 0.001
AED-Concernsa 2.82 (0.74) 2.61 (0.80) t(392)=2.69, p b 0.01
NCDa 0.82 (0.98) 1.32 (1.07) t(392)=4.59, p b 0.001
General Harma 2.58 (0.57) 2.43 (0.57) t(392)=2.61, p b 0.05
General Overusea 3.17 (0.81) 2.93 (0.82) t(392)=2.82, p=0.050
General Beneﬁt 3.89 (0.52) 3.92 (0.55) t(393)=0.44, p N 0.05
PSMb 2.56 (0.77) 2.47 (0.80) t(391)=1.08, p N 0.05
Bold values indicate signiﬁcant differences at the 0.05 level.
a 1 patient missing.
b 2 patients missing.
Table 3
Logistic regression analysis of the odds of nonadherence predicted by beliefs.
OR [95% CI] p
AED-Necessity 0.608 [0.460, 0.802] b0.001
AED-Concerns 1.419 [1.087, 1.854] b0.01
NCD 0.624 [0.504, 0.771] b0.001
General Harm 1.622 [1.121, 2.346] b0.01
General Overuse 1.434 [1.111, 1.850] b0.01
General Beneﬁt 0.920 [0.632, 1.339] N0.05
PSM 1.155 [0.889, 1.500] N0.05
Bold differences indicate signiﬁcant predictors of nonadherence at the 0.05 level.
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However, the validity of using this approach within the current sample
has been explored within a previous paper [9]. Finally, the internal
consistency of two of the BMQ General subscales was poor within the
current sample, which may have meant that we underestimated the
magnitude of the relationships between general beliefs and speciﬁc
beliefs and adherence found within the current study. The small
number of items used within these scales and the use of single items
to assess disparate topics may have contributed to the low internal
consistency.
5. Conclusions
Despite its limitations, this study was the ﬁrst to quantify patients'
perceptions of AEDmedication inUKprimary care and to link perceptions
to adherence. The ﬁndings indicate that patients' personal evaluations of
AEDsmaydiffer fromthemedical viewyet appear to inﬂuence adherence.
Patients' implicit evaluations of their personal need for AEDs relative to
their concerns about the potential adverse consequences of taking AEDs
appear to be particularly salient.
Our ﬁndings support the utility of patients' beliefs about medicines
as an indicator of their likely adherence to AEDs. In addition, our results
suggest that groups of individuals who are less adherent, for example,
younger patients with epilepsy [31], may also have greater concerns
about AEDs andmore doubts about their personal need for AEDs. Unlike
the demographic and clinical factors also associated with adherence
within this sample [9], beliefs are more readily modiﬁable.
Within a clinical setting, the Necessity–Concerns Framework in-
formed that interventions which address maladaptive beliefs about
AEDsmay, therefore, hold the potential to increase adherence, partly
reducing inequalities in healthcare and improving the quality of life
Low AED-
Necessity
Indifferent
Skeptical Ambivalent
Accepting
High AED-Concerns
High AED-
Necessity
Low AED-Concerns
61.9% 44.4%
41.0% 28.8%
Fig. 7. Rates of nonadherence among participants in each attitudinal group based on AED-Necessity and AED-Concerns scores.
Table 4
Seizure history and beliefs about medicines.
Number of seizures in the past year None
n=222
m (sd)
≥1 seizure
n=171
m (sd)
AED-Necessity 3.70 (0.73) 3.99 (0.78) t(390)= 3.78, p b 0.001
AED-Concerns 2.51 (0.74) 2.93 (0.78) t(389)= 5.48, p b 0.001
NCD 1.19 (1.00) 1.05 (1.13) t(389)=1.27, p N 0.05
General Harm 2.40 (0.52) 2.58 (0.62) t(390)= 3.16, p b 0.01
General Overuse 2.97 (0.78) 3.08 (0.88) t(390)=1.32, p N 0.05
General Beneﬁt 3.93 (0.56) 3.87 (0.53) t(391)=1.06, p N 0.05
PSM 2.36 (0.76) 2.68 (0.77) t(389)= 4.16, p b 0.001
Time since last seizure b1 year
n=155
m (sd)
1–5 years
n=98
m (sd)
N5 years
n=95
m (sd)
AED-Necessity 4.00 (0.78) 3.77 (0.74) 3.54 (0.70) F(2,345)=11.21, p b 0.001
AED-Concerns 2.94 (0.78) 2.51 (0.69) 2.51 (0.80) F(2,344)=13.57, p b 0.001
NCD 1.06 (1.12) 1.26 (0.99) 1.03 (0.11) F(2,344)= 1.42, p N 0.05
General Harm 2.58 (0.62) 2.39 (0.52) 2.37 (0.54) F(2,345)=5.40, p b 0.01
General Overuse 3.10 (0.88) 2.94 (0.79) 3.03 (0.80) F(2,345)= 1.13, p N 0.05
General Beneﬁt 3.87 (0.55) 3.97 (0.57) 3.92 (0.52) F(2,346)= 1.12, p N 0.05
PSM 2.68 (0.77) 2.32 (0.79) 2.38 (0.75) F(2,344)=8.35, p b 0.001
Bold values indicate signﬁcant differences between groups at the 0.05 level.
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of patients. Using a valid and reliable questionnaire, AED-Necessity
beliefs and Concerns can be easily quantiﬁed, enabling the assessment
of patients' beliefs about their AEDs as part of adherence support.
Personalized interventions targeted to address individual patients' doubts
about AED necessity and concerns about potential adverse effects could
then be implemented. The systematic development of adherence support
targeted to address speciﬁc perceptual factors (e.g., necessity beliefs and
concerns) as well as practical barriers (such as capacity and resources
inﬂuencing the capability to adhere) is a priority for research andpractice.
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